Incannex share price races higher on 'pivotal' trial approval

This cannabis share is lighting up the market on Thursday.

| More on:
Researchers working with medical cannabis.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Incannex Healthcare Ltd (ASX: IHL) share price is on the move on Thursday.

In morning trade, the cannabis-focused pharmaceutical company's shares are up 4.5% to 12 cents.

Why is the Incannex share price rising?

Investors have been buying the company's shares today after it released an update on a clinical trial.

According to the release, Incannex has received approval from Bellberry Human Research Ethics Committee (HREC) for the lead site, Emeritus Research in Melbourne, for its Phase 2 clinical trial.

Management notes that the trial is pivotal in nature and will assess the safety and efficacy of IHL-675A in patients with rheumatoid arthritis (RA). IHL-675A is the company's proprietary anti-inflammatory combination drug product.

This trial follows the successful phase 1 clinical trial, whereby both active pharmaceutical ingredients, cannabidiol (CBD) and hydroxychloroquine sulphate (HCQ) were absorbed using IHL-675A. The drug product was also observed to be well tolerated, with no adverse events of concern.

What is phase 2?

The phase 2 study aims to build on the above and will assess the efficacy, safety, and tolerability of IHL-675A compared to the respective component active pharmaceutical ingredients (APIs), CBD and HCQ, and placebo.

As the treatments will be double-blinded, this means neither the investigators nor patients will know which treatment an individual is receiving.

Management notes the results of the trial will establish the safety and efficacy of IHL-675A in RA and will be a critical component of future regulatory applications. This includes contributing to the combination rule assessment in the US FDA's new drug application dossier.

Incannex Chief Scientific Officer Dr Mark Bleackley said:

HREC approval for the Phase 2 clinical trial is a key step in the development of IHL-675A for treatment of pain and reduced function associated with rheumatoid arthritis. We look forward to working with Emeritus and Avance to assess the effect of IHL675A in this patient population.

It is worth noting that Incannex announced plans to leave the ASX earlier this week. It plans to move its listing to the Nasdaq later this year.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Bored man sitting at his desk with his laptop.
Healthcare Shares

The Cochlear share price hit a 52-week low last week, is it time to buy?

Is this an opportunity worth hearing about?

Read more »

A businesswoman exhales a deep sigh after receiving bad news, and gets on with it.
Earnings Results

Cochlear share price sinks 10% on half-year result disappointment

Let's see why investors are hitting the sell button this morning.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

The CSL share price hit a 52-week low this week. Is it time to buy?

Is this beaten-up biotech a healthy opportunity?

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

With revenue up 9%, why does the NIB share price keep falling?

Will the ailing share price make a full recovery?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Guess how much $5,000 invested in Sigma shares in December 2023 is worth now!

Sigma shares have soared over the past year alongside the merger with Chemist Warehouse.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Healthcare Shares

Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads...

Read more »